MedChemComm

CORRECTION

View Article Online
View Journal | View Issue

Cite this: DOI: 10.1039/c6md90040b

Correction: Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9. See DOI: 10.1039/c6md00159a

Carl S. Rye,[a] Nicola E. A. Chessum,[a] Scott Lamont,[b] Kurt G. Pike,[b] Paul Faulder,[b] Julie Demeritt,[b] Paul Kemmitt,[b] Julie Tucker,[b] Lorenzo Zani,[a] Matthew D. Cheeseman,[a] Rosie Isaac,[b] Louise Goodwin,[b] Joanna Boros,[b] Florence Raynaud,[a] Angela Hayes,[a] Alan T. Henley,[a] Emmanuel de Billy,[a] Christopher J. Lynch,[a] Swee Y. Sharp,[a] Robert te Poele,[a] Lisa O' Fee,[a] Kevin M. Foote,[b] Stephen Green,[b] Paul Workman*[a] and Keith Jones*[a]

DOI: 10.1039/c6md90040b

www.rsc.org/medchemcomm

Correction for 'Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9' by Carl S. Rye *et al.*, *Med. Chem. Commun.*, 2016, **7**, 1580–1586.

The authors regret that there was an error in the structure of compound **26** (shown in Fig. 4 of the paper). The corrected structure is shown below.



SNS-032 (**26**)
HSF1 IC_{50} = 0.75 μM
CDK9 IC_{50} = 6 nM*
SRB GI_{50} = 0.37 μM

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

[a] *Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, UK. E-mail: Paul.Workman@icr.ac.uk*
[b] *AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK*